Difference between revisions of "Treosulfan (Ovastat)"
Jump to navigation
Jump to search
m |
m |
||
| (One intermediate revision by the same user not shown) | |||
| Line 8: | Line 8: | ||
==History of changes in EMA indication== | ==History of changes in EMA indication== | ||
| − | *2019-06-20: Initial authorization as Trecondi | + | *2019-06-20: Initial authorization as Trecondi. Treosulfan in combination with fludarabine is indicated as part of conditioning treatment prior to [[Allogeneic HSCT|allogeneic haematopoietic stem cell transplantation (alloHSCT)]] in adult patients with malignant and non-malignant diseases, and in paediatric patients older than one month with malignant diseases. |
| − | + | *2023-03-06: Treosulfan in combination with fludarabine is indicated as part of conditioning treatment prior to [[Allogeneic HSCT|allogeneic haematopoietic stem cell transplantation (alloHSCT)]] in adult patients and in paediatric patients older than one month with malignant and non-malignant diseases. | |
==Also known as== | ==Also known as== | ||
Latest revision as of 13:34, 1 October 2023
General information
Class/mechanism: Bifunctional alkylating agent which produces guanine-adenine intrastrand crosslinks, inducing apoptosis.
Route: IV, PO
Extravasation: irritant
Diseases for which it is used
History of changes in EMA indication
- 2019-06-20: Initial authorization as Trecondi. Treosulfan in combination with fludarabine is indicated as part of conditioning treatment prior to allogeneic haematopoietic stem cell transplantation (alloHSCT) in adult patients with malignant and non-malignant diseases, and in paediatric patients older than one month with malignant diseases.
- 2023-03-06: Treosulfan in combination with fludarabine is indicated as part of conditioning treatment prior to allogeneic haematopoietic stem cell transplantation (alloHSCT) in adult patients and in paediatric patients older than one month with malignant and non-malignant diseases.
Also known as
- Brand names: Ovastat, Trecondi